Navidea Biopharmaceuticals, Inc. (NAVBQ)
OTCMKTS · Delayed Price · Currency is USD
0.0000
-0.0001 (-99.00%)
At close: Feb 11, 2026

NAVBQ Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2022FY 2021FY 2020FY 2019FY 2018
Period Ending
Sep '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18
Net Income
-1.18-15.18-11.73-10.72-10.95-16.11
Depreciation & Amortization
0.110.10.080.070.140.15
Other Amortization
0.350.21----
Loss (Gain) From Sale of Assets
0.070.070.10.010.06-
Stock-Based Compensation
0.190.410.630.510.270.96
Other Operating Activities
-1.560.29-0.240.12-05.44
Change in Accounts Receivable
0.120.09-0.030.84-0.0712.93
Change in Inventory
-0.45-0.460.02-0.17--
Change in Accounts Payable
0.330.70.260.050.69-0.43
Change in Unearned Revenue
-0.030.760.010.010-0.02
Change in Other Net Operating Assets
-0.164.020.691.110.51.35
Operating Cash Flow
-9.71-8.99-10.22-8.17-9.354.28
Operating Cash Flow Growth
------92.76%
Capital Expenditures
-0.02-0.06-0.03-0.14--0.05
Sale of Property, Plant & Equipment
0--00.03-
Sale (Purchase) of Intangibles
-0.18-0.33-0.3-0.28-0.06-
Investment in Securities
0.75---0.81
Investing Cash Flow
7.98-0.39-0.33-0.410.770.95
Long-Term Debt Issued
-2.5-0.37--
Long-Term Debt Repaid
--0.52-0.49-0.37-0.36-0.4
Net Debt Issued (Repaid)
-0.611.98-0.49-0-0.36-0.4
Issuance of Common Stock
0.64004.447.093
Repurchase of Common Stock
---0.02---
Other Financing Activities
-0.14-1.01-0.07-0.21-0.57-7.15
Financing Cash Flow
17.1412.1110.216.16-4.55
Net Cash Flow
-0.74-2.241.561.62-2.430.68
Free Cash Flow
-9.73-9.05-10.24-8.31-9.354.23
Free Cash Flow Growth
------92.84%
Free Cash Flow Margin
-1594888.03%-13784.28%-1927.21%-908.15%-1422.07%361.68%
Free Cash Flow Per Share
-0.18-0.29-0.35-0.35-0.650.50
Cash Interest Paid
0.190.140.010.010.010.01
Levered Free Cash Flow
-7.77-2.29-3.56-8.11-6.850.14
Unlevered Free Cash Flow
-8.12-2.29-3.55-8.1-6.840.24
Change in Working Capital
-0.195.120.951.841.1213.83
Source: S&P Global Market Intelligence. Standard template. Financial Sources.